Resorcinol study
This article was originally published in The Tan Sheet
Executive Summary
HHS National Toxicology Program's recently released report on resorcinol concludes that there is "no evidence of carcinogenic activity in male F344/N rats given 50, 100, or 150 mg/kg" of resorcinol, and "no evidence of carcinogenic activity of resorcinol in male or female B6C3F[1] mice given 112 or 225 mg/kg" resorcinol. Resorcinol is the active ingredient in Menley & James' Acnomel Cream and Sandoz' BiCozene Creme. The ingredient was studied by NTP because of its potential for "consumer exposure and the absence of data on the effects of long- term exposure".
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning